Pediatric anthrax clinical management. Pediatrics 2014 May;133(5):e1411-36
Date
04/30/2014Pubmed ID
24777226Pubmed Central ID
PMC4479255DOI
10.1542/peds.2014-0563Scopus ID
2-s2.0-84899892740 (requires institutional sign-in at Scopus site) 46 CitationsAbstract
Anthrax is a zoonotic disease caused by Bacillus anthracis, which has multiple routes of infection in humans, manifesting in different initial presentations of disease. Because B anthracis has the potential to be used as a biological weapon and can rapidly progress to systemic anthrax with high mortality in those who are exposed and untreated, clinical guidance that can be quickly implemented must be in place before any intentional release of the agent. This document provides clinical guidance for the prophylaxis and treatment of neonates, infants, children, adolescents, and young adults up to the age of 21 (referred to as "children") in the event of a deliberate B anthracis release and offers guidance in areas where the unique characteristics of children dictate a different clinical recommendation from adults.
Author List
Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT, AAP Committee on Infectious Diseases and Disaster Preparedness Advisory CouncilAuthor
Rodney E. Willoughby MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAnthrax
Anthrax Vaccines
Bacillus anthracis
Biological Warfare Agents
Child
Child, Preschool
Ciprofloxacin
Doxycycline
Drug Therapy, Combination
Health Education
Humans
Infant
Infant, Newborn
Inservice Training
Pediatrics
United States
Young Adult
